Researchers assessed the association between Behçet disease and psoriasis and psoriatic arthritis, using data from the National Health Insurance Service of Korea.
Avacopan is noninferior, but not superior, to prednisone with respect to remission at week 26 for patients with ANCA-associated vasculitis.
In this interview, Richard Becker, MD, gives us an insight into COVID-19 vasculitis and its manifestations.
Researchers assessed glucocorticoid maintenance dose and treatment duration on outcomes in patients with ANCA-associated vasculitis.
Study authors evaluated the effect of complement C5a receptor inhibitor avacopan on renal function in ANCA-associated vasculitis.
Researchers assessed thyroid disease risk between the different forms of ANCA-associated vasculitis (AAV), and compared the clinical features of AAV in patients with and without thyroid disease.
In a safety outcome analysis, researchers assessed treatment-related damage in patients with elderly-onset ANCA-associated vasculitis.
Researchers performed a systematic review to identify cases of infection-induced antimyeloperoxidase ANCA-associated vasculitis.
Authors of this case study reported the first case of neutrophilic arterial vasculitis in COVID-19.
Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.